Your browser doesn't support javascript.
loading
Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.
Liu, Shiqin; Shen, Michelle; Hsu, En-Chi; Zhang, Chiyuan Amy; Garcia-Marques, Fernando; Nolley, Rosalie; Koul, Kashyap; Rice, Meghan A; Aslan, Merve; Pitteri, Sharon J; Massie, Charlie; George, Anne; Brooks, James D; Gnanapragasam, Vincent J; Stoyanova, Tanya.
Afiliação
  • Liu S; Department of Radiology, Stanford University, Stanford, CA, USA.
  • Shen M; Canary Center at Stanford for Cancer Early Detection, Stanford University, Palo Alto, CA, USA.
  • Hsu EC; Department of Radiology, Stanford University, Stanford, CA, USA.
  • Zhang CA; Canary Center at Stanford for Cancer Early Detection, Stanford University, Palo Alto, CA, USA.
  • Garcia-Marques F; Department of Radiology, Stanford University, Stanford, CA, USA.
  • Nolley R; Canary Center at Stanford for Cancer Early Detection, Stanford University, Palo Alto, CA, USA.
  • Koul K; Department of Urology, Stanford University, Stanford, CA, USA.
  • Rice MA; Department of Radiology, Stanford University, Stanford, CA, USA.
  • Aslan M; Canary Center at Stanford for Cancer Early Detection, Stanford University, Palo Alto, CA, USA.
  • Pitteri SJ; Department of Urology, Stanford University, Stanford, CA, USA.
  • Massie C; Department of Radiology, Stanford University, Stanford, CA, USA.
  • George A; Canary Center at Stanford for Cancer Early Detection, Stanford University, Palo Alto, CA, USA.
  • Brooks JD; Department of Radiology, Stanford University, Stanford, CA, USA.
  • Gnanapragasam VJ; Canary Center at Stanford for Cancer Early Detection, Stanford University, Palo Alto, CA, USA.
  • Stoyanova T; Department of Radiology, Stanford University, Stanford, CA, USA.
Br J Cancer ; 124(5): 896-900, 2021 03.
Article em En | MEDLINE | ID: mdl-33288843
ABSTRACT
Distinguishing clinically significant from indolent prostate cancer (PC) is a major clinical challenge. We utilised targeted protein biomarker discovery approach to identify biomarkers specific for pro-metastatic PC. Serum samples from the cancer-free group; Cambridge Prognostic Group 1 (CPG1, low risk); CPG5 (high risk) and metastatic disease were analysed using Olink Proteomics panels. Tissue validation was performed by immunohistochemistry in a radical prostatectomy cohort (n = 234). We discovered that nine proteins (pleiotrophin (PTN), MK, PVRL4, EPHA2, TFPI-2, hK11, SYND1, ANGPT2, and hK14) were elevated in metastatic PC patients when compared to other groups. PTN levels were increased in serum from men with CPG5 compared to benign and CPG1. High tissue PTN level was an independent predictor of biochemical recurrence and metastatic progression in low- and intermediate-grade disease. These findings suggest that PTN may represent a novel biomarker for the presence of poor prognosis local disease with the potential to metastasise warranting further investigation.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prostatectomia / Neoplasias da Próstata / Proteínas de Transporte / Biomarcadores Tumorais / Citocinas Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Br J Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prostatectomia / Neoplasias da Próstata / Proteínas de Transporte / Biomarcadores Tumorais / Citocinas Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Br J Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos